Sumo Medexim Profile
Key Indicators
- Authorised Capital ₹ 5.00 M
as on 23-10-2024
- Paid Up Capital ₹ 4.35 M
as on 23-10-2024
- Company Age 29 Year, 7 Months
- Last Filing with ROC 31 Mar 2023
- Open Charges ₹ 103.50 Cr
as on 23-10-2024
- Revenue -8.11%
(FY 2023)
- Profit 17.84%
(FY 2023)
- Ebitda 85.53%
(FY 2023)
- Net Worth 2.54%
(FY 2023)
- Total Assets 1.18%
(FY 2023)
About Sumo Medexim
The Company is engaged in the Financial Services Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 5.00 M and a paid-up capital of Rs 4.35 M.
The company currently has active open charges totaling ₹103.50 Cr.
Sanjay Sanghavi, Manherlal Sanghavi, and Shilpa Sanghavi serve as directors at the Company.
- CIN/LLPIN
U24239MH1995PLC088349
- Company No.
088349
- Company Classification
Public Limited Indian Non-Government Company
- Incorporation Date
15 May 1995
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Mumbai
Industry
Company Details
- Location
Mumbai, Maharashtra, India
- Telephone
- Email Address
- Website
-
- Social Media-
Who are the key members and board of directors at Sumo Medexim?
Board Members(3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Sanjay Sanghavi  | Director | 15-May-1995 | Current |
| Manherlal Sanghavi | Director | 15-May-1995 | Current |
| Shilpa Sanghavi | Director | 15-May-1995 | Current |
Financial Performance and Corporate Structure Insights of Sumo Medexim.
Sumo Medexim Limited, for the financial year ended 2023, experienced Minor drop in revenue, with a 8.11% decrease. The company also saw a substantial improvement in profitability, with a 17.84% increase in profit. The company's net worth moved up by a moderate rise of 2.54%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations | |||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Sumo Medexim?
In 2023, Sumo Medexim had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
- Bestworth Infrastructure LlpActive 9 years 9 months
Sanjay Sanghavi and Shilpa Sanghavi are mutual person
- Bulltext Infrastructure LlpActive 9 years 9 months
Sanjay Sanghavi and Shilpa Sanghavi are mutual person
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Others Creation Date: 30 Mar 2020 | ₹90.50 Cr | Open |
Reliance Home Finance Private Limited Creation Date: 01 Jun 2011 | ₹13.00 Cr | Open |
How Many Employees Work at Sumo Medexim?
Unlock and access historical data on people associated with Sumo Medexim, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Sumo Medexim, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Sumo Medexim's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
